Improved plasma cholesterol efflux capacity from human macrophages in patients with hyperalphalipoproteinemia

Atherosclerosis

Volumn 234, Issue 1, 2014, Pages 193-199

  El Khoury, Petra ^a,b   Plengpanich, Wanee ^c   Frisdal, Eric ^a   Le Goff, Wilfried ^a,d   Khovidhunkit, Weerapan ^c   Guerin, Maryse ^a,d  

^a SORBONNE UNIVERSITÉ   (France)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d Institute for Cardio metabolism and Nutrition   (France)

Author keywords

CETP; Cholesterol efflux; Genetic deficiency; HDL; Hepatic lipase; Macrophage; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; LIVER TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CELL STIMULATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPOPROTEINEMIA; FEMALE; FRACTIONATION; HUMAN; HYPERALPHALIPOPROTEINEMIA; MACROPHAGE; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TRANSPORT; BLOOD; DEFICIENCY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; METABOLISM;

ADULT; AGED; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; HUMANS; LIPID METABOLISM, INBORN ERRORS; MACROPHAGES; MALE; MIDDLE AGED;

EID: 84897949596     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.02.032     Document Type: Article

References (50)

1. Brewer H.B. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003, 92:23K-29K.
2. Shaw J.A., Bobik A., Murphy A., et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008, 103:1084-1091.
3. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. NEngl J Med 2011, 364:127-135.
4. Li X.M., Tang W.H., Mosior M.K., et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013, 33:1696-1705.
5. Khetarpal S.A., Edmondson A.C., Raghavan A., et al. Mining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterol. PLoS Genet 2011, 7:8.
6. Agerholm-Larsen B., Nordestgaard B.G., Steffensen R., Jensen G., Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000, 101:1907-1912.
7. Okamura T., Sekikawa A., Kadowaki T., et al. Cholesteryl ester transfer protein, coronary calcium, and intima-media thickness of the carotid artery in middle-age Japanese men. Am J Cardiol 2009, 104:818-822.
8. Ruel I.L., Couture P., Cohn J.S., Bensadoun A., Marcil M., Lamarche B. Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism. JLipid Res 2004, 45:1528-1537.
9. Ishigami M., Yamashita S., Sakai N., et al. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. JBiochem 1994, 116:257-262.
10. Matsuura F., Wang N., Chen W., Jiang X.C., Tall A.R. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. JClin Invest 2006, 116:1435-1442.
11. Miwa K., Inazu A., Kawashiri M., et al. Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin Chim Acta 2009, 402:19-24.
12. Ohta T., Nakamura R., Takata K., et al. Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. JLipid Res 1995, 36:696-704.
13. Catalano G., Julia Z., Frisdal E., et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009, 29:268-275.
14. Yvan-Charvet L., Matsuura F., Wang N., et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007, 27:1132-1138.
15. Yvan-Charvet L., Kling J., Pagler T., et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010, 30:1430-1438.
16. Larrede S., Quinn C.M., Jessup W., et al. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol 2009, 29:1930-1936.
17. Khovidhunkit W., Chartyingcharoen P., Siriwong S., Limumpornpetch P., Plengpanich W. Resequencing CETP, LIPC and LIPG genes in Thai subjects with hyperalphalipoproteinemia. Am J Cardiol 2012, 110:62-66.
18. Plengpanich W., Le Goff W., Poolsuk S., Julia Z., Guerin M., Khovidhunkit W. CETP deficiency due to a novel mutation in the CETP gene promoter and its effect on cholesterol efflux and selective uptake into hepatocytes. Atherosclerosis 2011, 216:370-373.
19. Plengpanich W., Tongkobpetch S., Shotelersuk V., Le Goff W., Khovidhunkit W. Functional characterization of novel variants in the CETP promoter and the LIPC gene in subjects with hyperalphalipoproteinemia. Clin Chim Acta 2013, 416:92-95.
20. Guerin M., Bruckert E., Dolphin P.J., Turpin G., Chapman M.J. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996, 16:763-772.
21. Villard E.F., El Khoury P., Duchene E., et al. Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women. Arterioscler Thromb Vasc Biol 2012, 32:2341-2349.
22. Zimetti F., Weibel G.K., Duong M., Rothblat G.H. Measurement of cholesterol bidirectional flux between cells and lipoproteins. JLipid Res 2006, 47:605-613.
23. Rothblat G.H., Phillips M.C. Mechanism of cholesterol efflux from cells. Effects of acceptor structure and concentration. JBiol Chem 1982, 257:4775-4782.
24. Gelissen I.C., Harris M., Rye K.A., et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006, 26:534-540.
25. Le Goff W., Settle M., Greene D.J., Morton R.E., Smith J.D. Reevaluation of the role of the multidrug-resistant P-glycoprotein in cellular cholesterol homeostasis. JLipid Res 2006, 47:51-58.
26. de la Llera-Moya M., Rothblat G.H., Connelly M.A., et al. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. JLipid Res 1999, 40:575-580.
27. Wang N., Lan D., Chen W., Matsuura F., Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004, 101:9774-9779.
28. Chan D.C., Hoang A., Barrett P.H., et al. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux. JClin Endocrinol Metab 2012, 97. 2012-1522.
29. Hoang A., Drew B.G., Low H., et al. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur Heart J 2011, 33:657-665.
30. Sankaranarayanan S., Oram J.F., Asztalos B.F., et al. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. JLipid Res 2009, 50:275-284.
31. Treguier M., Moreau M., Sposito A., Chapman M.J., Huby T. LDL particle subspecies are distinct in their capacity to mediate free cholesterol efflux via the SR-BI/Cla-1 receptor. Biochim Biophys Acta 2007, 1771:129-138.
32. Greene D.J., Skeggs J.W., Morton R.E. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). JBiol Chem 2001, 276:4804-4811.
33. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. JClin Invest 1996, 97:2917-2923.
34. Parks J.S., Li H., Gebre A.K., Smith T.L., Maeda N. Effect of apolipoprotein A-I deficiency on lecithin:cholesterol acyltransferase activation in mouse plasma. JLipid Res 1995, 36:349-355.
35. Cheung M.C., Wang D.B., Lum K.D., Albers J.J. Cholesterol esterification by lecithin-cholesterol acyltransferase in A-I-free plasma. Biochim Biophys Acta 1988, 962:258-264.
36. Zorich N., Jonas A., Pownall H.J. Activation of lecithin cholesterol acyltransferase by human apolipoprotein E in discoidal complexes with lipids. JBiol Chem 1985, 260:8831-8837.
37. Asztalos B.F., Horvath K.V., Kajinami K., et al. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. JLipid Res 2004, 45:448-455.
38. Rye K.A., Jauhiainen M., Barter P.J., Ehnholm C. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. JLipid Res 1998, 39:613-622.
39. Murakami T., Michelagnoli S., Longhi R., et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995, 15:1819-1828.
40. Sich D., Saidi Y., Giral P., et al. Hyperalphalipoproteinemia: characterization of a cardioprotective profile associating increased high-density lipoprotein2 levels and decreased hepatic lipase activity. Metabolism 1998, 47:965-973.
41. de La Llera-Moya M., Connelly M.A., Drazul D., et al. Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. JLipid Res 2001, 42:1969-1978.
42. Connelly M.A., Williams D.L. Scavenger receptor BI: a scavenger receptor with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol 2004, 15:287-295.
43. Martinez L.O., Jacquet S., Esteve J.P., et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003, 421:75-79.
44. Jacquet S., Malaval C., Martinez L.O., et al. The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cell Mol Life Sci 2005, 62:2508-2515.
45. Fabre A.C., Malaval C., Ben Addi A., et al. P2Y13 receptor is critical for reverse cholesterol transport. Hepatology 2010, 52:1477-1483.
46. Agerholm-Larsen B., Tybjaerg-Hansen A., Schnohr P., Steffensen R., Nordestgaard B.G. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City Heart Study. Circulation 2000, 102:2197-2203.
47. Borggreve S.E., Hillege H.L., Dallinga-Thie G.M., et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J 2007, 28:1012-1018.
48. Winkelmann B.R., Marz W., Boehm B.O., et al. Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001, 2:S1-S73.
49. Ritsch A., Scharnagl H., Eller P., et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010, 121:366-374.
50. Scharnagl H., Heuschneider C., Sailer S., Kleber M.E., Marz W. Ritsch a decreased cholesterol efflux capacity in patients with low CETP plasma levels. Eur J Clin Invest 2014, 2014:12248.